![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Danish Headache Center EUROHEAD-partners |
---|---|
Information provided by: | Danish Headache Center |
ClinicalTrials.gov Identifier: | NCT00687947 |
The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.
Condition | Intervention |
---|---|
Familial Hemiplegic Migraine Migraine With Aura Healthy |
Drug: CGRP |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Active Control, Parallel Assignment, Pharmacodynamics Study |
Official Title: | CGRP-Induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls |
Estimated Enrollment: | 30 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | August 2008 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
MA-patients
|
Drug: CGRP
CGRP (0.5 ug/min) infused intravenously over 20 min
|
2: Experimental
FHM-patients
|
Drug: CGRP
CGRP (0.5 ug/min) infused intravenously over 20 min
|
3: Active Comparator
Healthy controls
|
Drug: CGRP
CGRP (0.5 ug/min) infused intravenously over 20 min
|
Calcitonion gene-related peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous migraine attacks with an inhibitor of CGRP is effective in many patients. These data show that CGRP is involved in migraine pathophysiology.
The importance of migraine genetics is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Patients and controls:
On the study day:
Contact: Jakob Møller Hansen, MD | 45-4323-2713 | jamoha01@glo.regionh.dk |
Denmark | |
Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital | Recruiting |
Glostrup, Copenhagen, Denmark, 2600 | |
Principal Investigator: Jakob Møller Hansen, MD |
Principal Investigator: | Jakob Møller Hansen, MD | Danish Headache Center |
Responsible Party: | Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital ( Jakob Møller Hansen, MD ) |
Study ID Numbers: | FHM-CGRP-MA-2008 |
Study First Received: | May 28, 2008 |
Last Updated: | May 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00687947 |
Health Authority: | Denmark: Ethics Committee |
FHM MA healthy controls CGRP |
Calcitonin Gene-Related Peptide Calcitonin Migraine Disorders Headache Central Nervous System Diseases Headache Disorders, Primary |
Migraine with Aura Healthy Brain Diseases Salmon calcitonin Headache Disorders |
Vasodilator Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Bone Density Conservation Agents Cardiovascular Agents Pharmacologic Actions |